Antibody-drug conjugates (ADCs) targeting TROP-2 in lung cancer

References

• Shvartsur A, Bonavida B. Trop2 and its overexpression in cancers: regulation and clinical/therapeutic implications. Genes Cancer. 2015 Mar;6(3–4):84–105.
   PubMedGoogle Scholar
• Zeng P, Chen MB, Zhou LN, et al. Impact of TROP2 expression on prognosis in solid tumors: a systematic review and meta-analysis. Sci Rep. 2016 Sep 20;6(1):33658.
   PubMedGoogle Scholar
• Jiang A, Gao X, Zhang D, et al. Expression and clinical significance of the Trop-2 gene in advanced non-small cell lung carcinoma. Oncol Lett. 2013 Aug;6(2):375–380. DOI:10.3892/ol.2013.1368
   PubMed Web of Science ®Google Scholar
• Drago JZ, Modi S, Chandarlapaty S. Unlocking the potential of antibody-drug conjugates for cancer therapy. Nat Rev Clin Oncol. 2021 Jun;18(6):327–344.
   PubMed Web of Science ®Google Scholar
• Strebhardt K, Ullrich A. Paul Ehrlich’s magic bullet concept: 100 years of progress. Nat Rev Cancer. 2008 Jun;8(6):473–480.
   PubMed Web of Science ®Google Scholar
• Richardson NC, Kasamon YL, Chen H, et al. FDA approval summary: brentuximab vedotin in first-line treatment of peripheral T-Cell lymphoma. Oncology. 2019 May;24(5):e180–187.
   Google Scholar
• Amiri-Kordestani L, Blumenthal GM, Xu QC, et al. FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436–4441.
   PubMed Web of Science ®Google Scholar
• Narayan P, Osgood CL, Singh H, et al. FDA approval summary: fam-trastuzumab deruxtecan-nxki for the treatment of unresectable or metastatic HER2-positive breast cancer. Clin Cancer Res. 2021 Aug 15;27(16):4478–4485.
   PubMed Web of Science ®Google Scholar
• Tagawa ST, Balar AV, Petrylak DP, et al. TROPHY-U-01: a phase ii open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors. J Clin Oncol. 2021 Aug 1;39(22):2474–2485.
   PubMed Web of Science ®Google Scholar
• Bardia A, Hurvitz SA, Tolaney SM, et al. Sacituzumab govitecan in metastatic triple-negative breast cancer. N Engl J Med. 2021 Apr 22;384(16):1529–1541.
   PubMed Web of Science ®Google Scholar
• Lenárt S, Lenárt P, Šmarda J, et al. Trop2: jack of all trades, master of none. Cancers (Basel). 2020 Nov 11;12(11):3328.
   PubMed Web of Science ®Google Scholar
• Stein R, Basu A, Chen S, et al. Specificity and properties of MAb RS7-3G11 and the antigen defined by this pancarcinoma monoclonal antibody. Int J Cancer. 1993 Dec 2;55(6):938–946.
   PubMed Web of Science ®Google Scholar
• McDougall AR, Tolcos M, Hooper SB, et al. Trop2: from development to disease. Dev Dyn. 2015 Feb;244(2):99–109.
   PubMed Web of Science ®Google Scholar
• Goldenberg DM, Stein R, Sharkey RM. The emergence of trophoblast cell-surface antigen 2 (TROP-2) as a novel cancer target. Oncotarget. 2018 Jun 22;9(48):28989–29006.
   PubMedGoogle Scholar
• Basu A, Goldenberg DM, Stein R. The epithelial/carcinoma antigen EGP-1, recognized by monoclonal antibody RS7-3G11, is phosphorylated on serine 303. Int J Cancer. 1995 Aug 9;62(4):472–479.
   PubMed Web of Science ®Google Scholar
• El Sewedy T, Fornaro M, Alberti S. Cloning of the murine TROP2 gene: conservation of a PIP2-binding sequence in the cytoplasmic domain of TROP-2. Int J Cancer. 1998 Jan 19;75(2):324–330.
   PubMed Web of Science ®Google Scholar
• Ciccarelli FD, Acciarito A, Alberti S. Large and diverse numbers of human diseases with HIKE mutations. Hum Mol Genet. 2000 Apr 12;9(6):1001–1007.
   PubMed Web of Science ®Google Scholar
• Guerra E, Trerotola M, Aloisi AL, et al. The Trop-2 signalling network in cancer growth. Oncogene. 2013 Mar 21;32(12):1594–1600.
   PubMed Web of Science ®Google Scholar
• Trerotola M, Li J, Alberti S, et al. Trop-2 inhibits prostate cancer cell adhesion to fibronectin through the beta1 integrin-RACK1 axis. J Cell Physiol. 2012 Nov;227(11):3670–3677.
   PubMed Web of Science ®Google Scholar
• Zhao W, Jia L, Kuai X, et al. The role and molecular mechanism of Trop2 induced epithelial-mesenchymal transition through mediated beta-catenin in gastric cancer. Cancer Med. 2019 Mar;8(3):1135–1147.
   PubMed Web of Science ®Google Scholar
• Cubas R, Zhang S, Li M, et al. Trop2 expression contributes to tumor pathogenesis by activating the ERK MAPK pathway. Mol Cancer. 2010 Sep 21;9(1):253.
   PubMedGoogle Scholar
• Bakiri L, Macho-Maschler S, Custic I, et al. Fra-1/AP-1 induces EMT in mammary epithelial cells by modulating Zeb1/2 and TGFbeta expression. Cell Death Differ. 2015 Feb;22(2):336–350.
   PubMed Web of Science ®Google Scholar
• Stoyanova T, Goldstein AS, Cai H, et al. Regulated proteolysis of Trop2 drives epithelial hyperplasia and stem cell self-renewal via beta-catenin signaling. Genes Dev. 2012 Oct 15;26(20):2271–2285.
   PubMed Web of Science ®Google Scholar
• Trerotola M, Jernigan DL, Liu Q, et al. Trop-2 promotes prostate cancer metastasis by modulating beta(1) integrin functions. Cancer Res. 2013 May 15;73(10):3155–3167.
   PubMed Web of Science ®Google Scholar
• Trerotola M, Cantanelli P, Guerra E, et al. Upregulation of Trop-2 quantitatively stimulates human cancer growth. Oncogene. 2013;32(2):222–233. DOI:10.1038/onc.2012.36
   PubMed Web of Science ®Google Scholar
• Dongre A, Weinberg RA. New insights into the mechanisms of epithelial-mesenchymal transition and implications for cancer. Nat Rev Mol Cell Biol. 2019 Feb;20(2):69–84.
   PubMed Web of Science ®Google Scholar
• Ambrogi F, Fornili M, Boracchi P, et al. Trop-2 is a determinant of breast cancer survival. PLoS ONE. 2014;9(5):e96993. DOI:10.1371/journal.pone.0096993
   PubMed Web of Science ®Google Scholar
• Cortesi M, Zanoni M, Maltoni R, et al. TROP2 (trophoblast cell-surface antigen 2): a drug target for breast cancer. Expert Opin Ther Targets. 2022 Jul;26(7):593–602.
   PubMed Web of Science ®Google Scholar
• Stepan LP, Trueblood ES, Hale K, et al. Expression of Trop2 cell surface glycoprotein in normal and tumor tissues: potential implications as a cancer therapeutic target. J Histochem Cytochem. 2011 Jul;59(7):701–710.
   PubMed Web of Science ®Google Scholar
• Liao S, Wang B, Zeng R, et al. Recent advances in trophoblast cell-surface antigen 2 targeted therapy for solid tumors. Drug Dev Res. 2021 Dec;82(8):1096–1110.
   PubMed Web of Science ®Google Scholar
• Dum D, Hube-Magg C, Simon R, et al. 83P patterns of trophoblast cell surface antigen 2 (TROP2) and epithelial cell adhesion molecule (EPCAM) expression in human tumors: a tissue microarray study on 14,766 tumors. Ann Oncol. 2022;33:S578.
   PubMed Web of Science ®Google Scholar
• Bignotti E, Todeschini P, Calza S, et al. Trop-2 overexpression as an independent marker for poor overall survival in ovarian carcinoma patients. Eur J Cancer. 2010 Mar;46(5):944–953.
   PubMed Web of Science ®Google Scholar
• Pak MG, Shin DH, Lee CH, et al. Significance of EpCAM and TROP2 expression in non-small cell lung cancer. World J Surg Oncol. 2012 Apr 6;10(1):53.
   PubMedGoogle Scholar
• Tang G, Tang Q, Jia L, et al. High expression of TROP2 is correlated with poor prognosis of oral squamous cell carcinoma. Pathol Res Pract. 2018 Oct;214(10):1606–1612.
   PubMed Web of Science ®Google Scholar
• Inamura K, Yokouchi Y, Kobayashi M, et al. Association of tumor TROP2 expression with prognosis varies among lung cancer subtypes. Oncotarget. 2017 Apr 25;8(17):28725–28735.
   PubMedGoogle Scholar
• Omori S, Muramatsu K, Kawata T, et al. Trophoblast cell-surface antigen 2 expression in lung cancer patients and the effects of anticancer treatments. J Cancer Res Clin Oncol. 2022 Sep;148(9):2455–2463.
   PubMed Web of Science ®Google Scholar
• Omori S, Muramatsu K, Kawata T, et al. Trophoblast cell-surface antigen 2 expression in lung cancer patients and the effects of anticancer treatments. J Cancer Res Clin Oncol. 2021;148(9):2455–2463. DOI:10.1007/s00432-021-03784-3
   PubMed Web of Science ®Google Scholar
• DeVita VT Jr., Rosenberg SA. Two hundred years of cancer research. N Engl J Med. 2012 Jun 7;366(23):2207–2214.
   PubMed Web of Science ®Google Scholar
• Yaghoubi S, Karimi MH, Lotfinia M, et al. Potential drugs used in the antibody-drug conjugate (ADC) architecture for cancer therapy. J Cell Physiol. 2020 Jan;235(1):31–64.
   PubMed Web of Science ®Google Scholar
• Abdollahpour-Alitappeh M, Lotfinia M, Gharibi T, et al. Antibody-drug conjugates (ADCs) for cancer therapy: strategies, challenges, and successes. J Cell Physiol. 2019 May;234(5):5628–5642.
   PubMed Web of Science ®Google Scholar
• Baron J, Wang ES. Gemtuzumab ozogamicin for the treatment of acute myeloid leukemia. Expert Rev Clin Pharmacol. 2018 Jun;11(6):549–559.
   PubMed Web of Science ®Google Scholar
• Li BT, Smit EF, Goto Y, et al. Trastuzumab deruxtecan in HER2-mutant non–small-cell lung cancer. N Engl J Med. 2022;386(3):241–251. DOI:10.1056/NEJMoa2112431
   PubMed Web of Science ®Google Scholar
• Son S, Shin S, Rao NV, et al. Anti-Trop2 antibody-conjugated bioreducible nanoparticles for targeted triple negative breast cancer therapy. Int j biol macromol. 2018 Apr 15;110:406–415.
   PubMed Web of Science ®Google Scholar
• Mao Y, Wang X, Zheng F, et al. The tumor-inhibitory effectiveness of a novel anti-Trop2 fab conjugate in pancreatic cancer. Oncotarget. 2016 Apr 26;7(17):24810–24823.
   PubMedGoogle Scholar
• Strop P, Tran TT, Dorywalska M, et al. RN927C, a site-specific Trop-2 Antibody-Drug Conjugate (ADC) with Enhanced stability, is highly efficacious in preclinical solid tumor models. Mol Cancer Ther. 2016 Nov;15(11):2698–2708.
   PubMed Web of Science ®Google Scholar
• Goldenberg DM, Cardillo TM, Govindan SV, et al. Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC). Oncotarget. 2015 Sep 8;6(26):22496–22512.
   PubMedGoogle Scholar
• Cardillo TM, Govindan SV, Sharkey RM, et al. Humanized anti-Trop-2 IgG-SN-38 conjugate for effective treatment of diverse epithelial cancers: preclinical studies in human cancer xenograft models and monkeys. Clin Cancer Res. 2011 May 15;17(10):3157–3169.
   PubMed Web of Science ®Google Scholar
• Cardillo TM, Rossi DL, Zalath MB, et al. Predictive biomarkers for sacituzumab govitecan efficacy in Trop-2-expressing triple-negative breast cancer. Oncotarget. 2020 Oct 27;11(43):3849–3862. DOI:10.18632/oncotarget.27766
   PubMedGoogle Scholar
• Sharkey RM, McBride WJ, Cardillo TM, et al. Enhanced delivery of SN-38 to human tumor xenografts with an anti-Trop-2-SN-38 antibody conjugate (Sacituzumab Govitecan). Clin Cancer Res. 2015 Nov 15;21(22):5131–5138.
   PubMed Web of Science ®Google Scholar
• Cheng Y, Yuan X, Tian Q, et al. Preclinical profiles of SKB264, a novel anti-TROP2 antibody conjugated to topoisomerase inhibitor, demonstrated promising antitumor efficacy compared to IMMU-132 [Original Research]. Front Oncol. 2022 Dec 23;12:12.
   Web of Science ®Google Scholar
• Okajima D, Yasuda S, Maejima T, et al. Datopotamab deruxtecan, a novel TROP2-directed antibody-drug conjugate, demonstrates potent antitumor activity by efficient drug delivery to tumor cells. Mol Cancer Ther. 2021 Dec;20(12):2329–2340. DOI:10.1158/1535-7163.MCT-21-0206
   PubMed Web of Science ®Google Scholar
• Ocean AJ, Starodub AN, Bardia A, et al. Sacituzumab govitecan (IMMU-132), an anti-Trop-2-SN-38 antibody-drug conjugate for the treatment of diverse epithelial cancers: safety and pharmacokinetics. Cancer. 2017 Oct 1;123(19):3843–3854.
   PubMed Web of Science ®Google Scholar
• King GT, Eaton KD, Beagle BR, et al. A phase 1, dose-escalation study of PF-06664178, an anti-Trop-2/aur0101 antibody-drug conjugate in patients with advanced or metastatic solid tumors. Invest New Drugs. 2018;36(5):836–847. DOI:10.1007/s10637-018-0560-6
   PubMed Web of Science ®Google Scholar
• Starodub AN, Ocean AJ, Shah MA, et al. First-in-human trial of a novel anti-Trop-2 antibody-SN-38 conjugate, sacituzumab govitecan, for the treatment of diverse metastatic solid tumors. Clin Cancer Res. 2015;21(17):3870–3878. DOI:10.1158/1078-0432.CCR-14-3321
   PubMed Web of Science ®Google Scholar
• Heist RS, Guarino MJ, Masters G, et al. Therapy of advanced non–small-cell lung cancer with an SN-38-Anti-Trop-2 drug conjugate, sacituzumab govitecan. J Clin Oncol. 2017;35(24):2790–2797. DOI:10.1200/JCO.2016.72.1894
   PubMed Web of Science ®Google Scholar
• Gray JE, Heist RS, Starodub AN, et al. Therapy of Small Cell Lung Cancer (SCLC) with a topoisomerase-I-inhibiting Antibody-Drug Conjugate (ADC) targeting Trop-2, sacituzumab govitecan. Clin Cancer Res. 2017 Oct 1;23(19):5711–5719. DOI:10.1158/1078-0432.CCR-17-0933
   PubMed Web of Science ®Google Scholar
• Bardia A, Messersmith WA, Kio EA, et al. Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I/II IMMU-132-01 basket trial. Ann Oncol. 2021;32(6):746–756. DOI:10.1016/j.annonc.2021.03.005
   PubMed Web of Science ®Google Scholar
• Garon E, Johnson M, Lisberg A, et al. MA03.02 TROPION-Pantumor01: updated results from the NSCLC cohort of the phase 1 study of datopotamab deruxtecan in solid tumors. J Thorac Oncol. 2021;16(10):S892–893. DOI:10.1016/j.jtho.2021.08.118
   Web of Science ®Google Scholar
• Garon EB, Johnson ML, Lisberg AE, et al. LBA49 efficacy of datopotamab deruxtecan (Dato-DXd) in patients (pts) with advanced/metastatic (adv/met) non-small cell lung cancer (NSCLC) and actionable genomic alterations (AGAs): preliminary results from the phase I TROPION-Pantumor01 study. Ann Oncol. 2021;32:S1326–1327.
   Web of Science ®Google Scholar
• Levy LP-A B, Rixe O, Su W-C, et al. MA13.07 TROPION-Lung02: initial results for datopotamab deruxtecan plus pembrolizumab and platinum chemotherapy in advanced NSCLC. J Thorac Oncol. 2022;17(9):S91. . DOI:10.1016/j.jtho.2022.07.152
   Web of Science ®Google Scholar
• Sandler AB. Irinotecan in small-cell lung cancer: the US experience. Oncology (Williston Park). 2001 Jan;15(1 Suppl 1):11–12.
   PubMedGoogle Scholar
• Lara PN Jr., Natale R, Crowley J, et al. Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124. J Clin Oncol. 2009 May 20;27(15):2530–2535.
   PubMed Web of Science ®Google Scholar
• Zatloukal P, Cardenal F, Szczesna A, et al. A multicenter international randomized phase III study comparing cisplatin in combination with irinotecan or etoposide in previously untreated small-cell lung cancer patients with extensive disease. Ann Oncol. 2010 Sep;21(9):1810–1816.
   PubMed Web of Science ®Google Scholar
• Shimizu T, Lisberg AE, Sands JM, et al. O2-1 datopotamab deruxtecan (Dato-DXd; DS-1062), a TROP2 ADC, in patients with advanced NSCLC: updated results of TROPION-Pantumor01 phase 1 study*. Ann Oncol. 2021;32:S285. .
   PubMed Web of Science ®Google Scholar
• Meric-Bernstam F, Spira AI, Lisberg AE, et al. TROPION-Pantumor01: dose analysis of the TROP2-directed antibody-drug conjugate (ADC) datopotamab deruxtecan (Dato-DXd, DS-1062) for the treatment (Tx) of advanced or metastatic non-small cell lung cancer (NSCLC). J Clin Oncol. 2021;39(15_suppl):9058. DOI:10.1200/JCO.2021.39.15_suppl.9058
   Web of Science ®Google Scholar
• Spira A, Lisberg A, Sands J, et al. OA03.03 datopotamab deruxtecan (Dato-DXd; DS-1062), a TROP2 ADC, in patients with advanced NSCLC: updated results of TROPION-Pantumor01 phase 1 study. J Thorac Oncol. 2021;16(3):S106–107. DOI:10.1016/j.jtho.2021.01.280
   Web of Science ®Google Scholar
• Millis SZ, Gatalica Z, Winkler J, et al. Predictive biomarker profiling of > 6000 breast cancer patients shows heterogeneity in TNBC, with treatment implications. Clin Breast Cancer. 2015 Dec;15(6):473–481 e3.
   PubMed Web of Science ®Google Scholar
• De Langen J, Cho BC, Piotrowska Z, et al. 1188tip ORCHARD platform study: osimertinib + datopotamab deruxtecan (Dato-DXd) cohort in patients (pts) with advanced NSCLC (aNSCLC) who have progressed on first-line (1L) osimertinib. Ann Oncol. 2022;33:S1091–1092.
   PubMed Web of Science ®Google Scholar